Anti-CD19 (FMC63) CAR特異性抗體蛋白

一、中文名稱：Anti-CD19 (FMC63)，CD19抗體，CAR特異性抗體蛋白

二、產(chǎn)品描述

FMC63抗體是一種針對人CD19的鼠單克隆抗體。CD19是目前CAR-T細胞治療領(lǐng)域中應(yīng)用最廣泛的靶點，大量研究表明，CD19是治療B細胞急性淋巴細胞白血?。˙-ALL）、慢性淋巴細胞白血?。–LL）和B細胞淋巴瘤等腫瘤有效且安全的靶點。而FMC63抗體的出現(xiàn)，使得CAR-T細胞治療更加精準(zhǔn)、安全。

三、相關(guān)產(chǎn)品

Anti-FMC63 scFv Monoclonal Antibody (SAA1996) (RAD10801)

Anti-Human CD19 scFv Antibody (FMC63) (RHD10803)

Anti-FMC63 scFv Monoclonal Antibody (SAA2162) (RAD10803)

Anti-Human CD19 Antibody (FMC63) (FHD10840)

四、產(chǎn)品詳情

名稱：Anti-FMC63 scFv Monoclonal Antibody (SAA1996) (RAD10801)

別名：FMC63，B-lymphocyte antigen CD19, B-lymphocyte surface antigen B4, Differentiation antigen CD19, T-cell surface antigen Leu-12, CD19, CD19, Anti-FMC63

貨號：RAD10801

宿主：Rabbit

同種型：IgG

克隆類型：Monoclonal

靶標(biāo)：Anti-human CD19 antibody clone FMC63, Idiotypic antibody

濃度：0.43 mg/ml

內(nèi)毒素水平：Please contact with the lab for this information.

純度：>95% as determined by SDS-PAGE.

純化方式：Protein A/G purified from cell culture supernatant.

Accession號：P15391

克隆號：SAA1996

應(yīng)用：ELISA

狀態(tài)：Liquid

保存溶液：0.01M PBS, pH 7.4.

穩(wěn)定性和存儲：Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term. (RAD10801)

五、參考文獻：

Solving the mystery of the FMC63-CD19 affinity. PMID: 38155191

CD19 CAR antigen engagement mechanisms and affinity tuning. PMID: 36867678

Safety and feasibility of anti-CD19 CAR T cells with fully human binding domains in patients with B-cell lymphoma. PMID: 31959992

Identification of Potent CD19 scFv for CAR T Cells through scFv Screening with NK/T-Cell Line. PMID: 33271901

Long-Term Follow-Up of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy. PMID: 33021872

A novel CD19/CD22/CD3 trispecific antibody enhances therapeutic efficacy and overcomes immune escape against B-ALL. PMID: 35981465

Enhanced CAR T cell expansion and prolonged persistence in pediatric patients with ALL treated with a low-affinity CD19 CAR. PMID: 31477906

Safety and efficacy of a novel anti-CD19 chimeric antigen receptor T cell product targeting a membrane-proximal domain of CD19 with fast on- and off-rates against non-Hodgkin lymphoma: a first-in-human study. PMID: 38066564

Efficacy and safety of CD19 CAR T constructed with a new anti-CD19 chimeric antigen receptor in relapsed or refractory acute lymphoblastic leukemia. PMID: 32894185

Activation priming and cytokine polyfunctionality modulate the enhanced functionality of low-affinity CD19 CAR T cells. PMID: 36453632

Clinical Impact of Single Nucleotide Polymorphism in CD-19 on Treatment Outcome in FMC63-CAR-T Cell Therapy. PMID: 37297020

T-cells engineered with a novel VHH-based chimeric antigen receptor against CD19 exhibit comparable tumoricidal efficacy to their FMC63-based counterparts. PMID: 36875091

Engineering of an Avidity-Optimized CD19-Specific Parallel Chimeric Antigen Receptor That Delivers Dual CD28 and 4-1BB Co-Stimulation. PMID: 35222427

Development and functional characterization of novel fully human anti-CD19 chimeric antigen receptors for T-cell therapy. PMID: 33432627

Fully human CD19-specific chimeric antigen receptors for T-cell therapy. PMID: 28202953

Stealth transgenes enable CAR-T cells to evade host immune responses. PMID: 38724463

Preparation and characterization of a chimeric CD19 monoclonal antibody. PMID: 1725979

Point mutation in CD19 facilitates immune escape of B cell lymphoma from CAR-T cell therapy. PMID: 33023981

Directed evolution-based discovery of ligands for in vivo restimulation of CAR-T cells. PMID: 38659938

CD19/CD20 dual-targeted chimeric antigen receptor-engineered natural killer cells exhibit improved cytotoxicity against acute lymphoblastic leukemia. PMID: 38475814

Differential cellular internalization of anti-CD19 and -CD22 immunotoxins results in different cytotoxic activity. PMID: 18676854

CAR T cells outperform CAR NK cells in CAR-mediated effector functions in head-to-head comparison. PMID: 38745250

Construction and characterisation of a functional CD19 specific single chain Fv fragment for immunotherapy of B lineage leukaemia and lymphoma. PMID: 9566763

Immunotherapy of B cell lymphoma with CD22-redirected CAR NK-92 cells. PMID: 37206593

Selective B cell depletion upon intravenous infusion of replication-incompetent anti-CD19 CAR lentivirus. PMID: 35755944

Fine Epitope Mapping of the CD19 Extracellular Domain Promotes Design. PMID: 31702909

Robust Antitumor Activity and Low Cytokine Production by Novel Humanized Anti-CD19 CAR T Cells. PMID: 33632869

Development of a Novel Anti-CD19 CAR Containing a Fully Human scFv and Three Costimulatory Domains. PMID: 35117999

Directed Evolution of Stabilized Monomeric CD19 for Monovalent CAR Interaction Studies and Monitoring of CAR-T Cell Patients. PMID: 33843201

A durable 4-1BB-based CD19 CAR-T cell for treatment of relapsed or refractory non-Hodgkin lymphoma. PMID: 35355931

詳情請咨詢Antibodysystem中國授權(quán)總代理-武漢佰樂博生物技術(shù)有限公司

網(wǎng)址：https://www.antibodysystem.com/product/17552.html

武漢佰樂博生物技術(shù)有限公司作為法國Antibodysystem品牌亞洲區(qū)授權(quán)總代理。提供近3萬種蛋白、抗體等核心生命科學(xué)試劑，旨在為生命科學(xué)科研工作者提供專業(yè)、全面、可靠的試劑產(chǎn)品。

試劑 | 耗材 | 定制 | 實驗服務(wù) | 供應(yīng)鏈

免費熱線：027-65279366 /18108604356